Dihydroergocryptine in the treatment of Parkinson's disease: A six months' double-blind clinical trial

E. Martignoni, C. Pacchetti, L. Sibilla, P. Bruggi, M. Pedevilla, G. Nappi

Research output: Contribution to journalArticlepeer-review

Abstract

The short-term efficacy of dihydro-α-ergocryptine (DEK), a hydrogenate ergot derivative with dopamine (DA) agonist properties was evaluated in 20 L-dopa (LD) stable responder parkinsonian patients by a 6-month double-blind randomized, placebo-controlled study. A motor improvement was found only in DEK-treated patients at mean daily doses of ~40 mg, ranging from 15 to 60 mg. The side effects never required the withdrawal of the drug or changes in its schedule. The authors demonstrate the efficacy and the good tolerability of DEK as a new DA agonist drug that can be added to LD in the treatment of parkinsonian patients.

Original languageEnglish
Pages (from-to)78-83
Number of pages6
JournalClinical Neuropharmacology
Volume14
Issue number1
Publication statusPublished - 1990

Keywords

  • Dihydro-α-ergocryptine (DEK)
  • Dopamine agonists
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Dihydroergocryptine in the treatment of Parkinson's disease: A six months' double-blind clinical trial'. Together they form a unique fingerprint.

Cite this